Dr. Matthew J. Ellis on Neoadjuvant Palbociclib in Primary Breast Cancer
Matthew J. Ellis, MD, PhD, director, Sue Smith Breast Center at Baylor College of Medicine, discusses a recent study of palbociclib in primary breast cancer.
Matthew J. Ellis, MD, PhD, director, Sue Smith Breast Center at Baylor College of Medicine, discusses a recent study of palbociclib in primary breast cancer. Ellis says while all the data on palbociclib prior to this study was in metastatic disease, this study looked at the treatment in the neoadjuvant setting for patient with breast cancer.
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More
